Chronic Plaque Psoriasis
Conditions
Brief summary
The expertise in the characterization of transcriptomics profile in lesional psoriatic skin and on the availability of innovative therapy for these patients.The investigators propose to follow the modification of the skin transcriptomics profile in psoriatic patients during successful Adalimumab biotherapy. Skin transcriptomics profiles of normal skin, psoriatic non lesional skin, and psoriatic lesional skin before and after biotherapy will be compared. The investigators will focus on the modification of the cytokine "signature" in these skin lesions and of some markers of keratinocyte inflammation. The modification of the transcriptomics profile induced by the biotherapy will be correlated to the clinical response Psoriasis Area and Severity Index.
Interventions
Adalimumab was administered subcutaneously at a dose of 80 mg at Week 0 and 40 mg every other week starting from Week 1 to Week 16.
Sponsors
Poitiers University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults with chronic plaque psoriasis involving at least 10% of body surface area with no previous biotherapy. * Adalimumab prescribed in usual practice
Exclusion criteria
* Patients presenting a contraindication to the use of Adalimumab: hypersensibility in Adalimumab or in one of the excipients. * Patients presenting an evolutionary tuberculosis or the other severe infections such as sepsis and opportunist infections. * Patients with one cardiac insufficiencies moderated in severe. * Patients under anakinra or abatacept. * Patients with a current participation in another study of clinical research.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area and Severity Index (PASI) | 4 weeks | Number of patients with a reduction in PASI score at 4 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dermatology Life Quality Index (DLQI) Scores | 4 weeks | Number of patients with a reduction in DLGI score at 4 weeks |
Countries
France
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Customized Mean age | 51.67 Years |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 15 |
| other Total, other adverse events | 0 / 15 |
| serious Total, serious adverse events | 0 / 15 |
Outcome results
None listed